What Are the Success Rates of Cannabis Treatments for AS? 

Cannabis success in treating Ankylosing Spondylitis (AS)  remains an open question. This article will examine how AS outcomes are quantified, what clinical data and patient-reported figures indicate regarding cannabis effect statistics, how cannabis compares to the rates of standard arthritis treatment, and what actual AS patient results look like.  

Measuring Success in AS Treatment 

“Success” in AS treatment covers several dimensions: reduced pain and inflammation, improved physical function, fewer flares, lower fatigue, and even reduction in conventional medication. Clinicians commonly use objective biomarkers like CRP or ESR, patient-centred outcomes like pain visual analogue scales (VAS), and functional questionnaires to gauge improvement. Success means a noticeable reduction in pain and stiffness that allows for daily activities, as well as an enhanced quality of life. 

What the Research Says About Cannabis Effectiveness 

Current clinical evidence for cannabis in AS is limited but emerging. A UK‑based prospective case series (82 participants with inflammatory arthritis, including AS) from the UK Medical Cannabis Registry found statistically significant improvements in pain scores, health questionnaires and anxiety measures at 1, 3, 6, and 12 months post-initiation of cannabis‑based medicinal products. 

In a separate cross-sectional study of rheumatology patients, roughly 24% of AS patients had tried medical cannabis; those who did reported average symptom relief of about 5.1 on a 10-point VAS. Another UK self-reported survey found AS users noting approximately a 32% reduction in pain after cannabis use. 

Meanwhile, a BMJ Open trial protocol is underway in Denmark to assess cannabinoid therapy (12 weeks of CBD with optional THC) in RA and AS. Though results aren’t published yet, it marks progress in the rigorous study of cannabis effect stats for AS. 

How Cannabis Compares to Other Arthritis Treatments 

NSAIDs and biologics, two common treatments for AS, typically have high success rates: Up to 70% of patients experience pain relief from NSAIDs, whereas at least 60–70% of patients experience significant symptom relief from biologics. Compared to these, cannabis currently demonstrates more modest success. 

For example, whereas most AS patients find relief from conventional therapies, only about 24–32% report significant pain relief from cannabis. Although it is unlikely to compete with well-established medications in terms of arthritis treatment rate or efficacy, cannabis may be used as a supplemental option, especially for patients who do not fully respond to first-line agents. 

Interpreting Patient-Reported Results 

Patient-reported AS outcomes offer valuable insight, yet they’re subjective and may be influenced by placebo or expectancy effects. For MSK patients broadly, about 64% rated cannabis as “somewhat or very effective”. In specific self-reports, AS outcomes vary: some experiences reflect full relief, others show partial benefit or none. 

Evaluations of both clinical and anecdotal AS patient results may also be influenced by side effects, which can range from mild sedation to cognitive effects. When assessing patient experiences, these results highlight the significance of cautious interpretation and clinician involvement. 

Final Thoughts 

Cannabis may help a subset of people with AS: self‑reports indicate pain relief in roughly 24–32%, with modest clinical improvement seen in patient‑reported scales. However, compared with NSAIDs and biologics, success rates remain lower and AS outcomes more variable. 

To increase trust in cannabis as a successful treatment for AS, more extensive, controlled trials are required, like the ongoing Danish RCT. Success with cannabis in the interim is individualised and should be evaluated in conjunction with conventional treatments while being closely monitored by a physician. 

Key Takeaways: 

• Cannabis success rates in AS are modest (pain reduction in about one‑quarter to one‑third of users). 

• While self‑reported AS outcomes can be promising, they aren’t a substitute for controlled clinical data. 

• Conventional treatments remain more reliable, but cannabis may offer added value for some. 

• Always interpret cannabis effect stats critically and consult your clinician before use. 

If you’re interested in exploring cannabis for AS as a treatment option, always consult a healthcare provider for advice tailored to your specific needs and condition. 

Learn more or book a medical cannabis consultation at LeafEase